Publications
Detailed Information
Combination Chemotherapy with S-1 and Platinum in Advanced Hepatocellular Carcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Su-Jung | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Yi, Nam-Joon | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Kang, Gyeong Hoon | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Jang, Ja-Joon | - |
dc.contributor.author | Suh, Kyung Suk | - |
dc.contributor.author | Yoon, Jung-Hwan | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.date.accessioned | 2012-06-26T05:59:54Z | - |
dc.date.available | 2012-06-26T05:59:54Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.citation | ANTICANCER RESEARCH; Vol.30 12; 5245-5250 | ko_KR |
dc.identifier.issn | 0250-7005 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77445 | - |
dc.description.abstract | Background: Based on its potent inhibition of dihydropyrimidine dehydrogenase (DPD), S-1 is expected to be more active than other flouropyrimidines against tumors with higher DPD activity, such as hepatocellular carcinoma (HCC). Patients and Methods: We retrospectively investigated the efficacy of S-1 and platinum in HCC. Patients received S-1 (80 mg/m(2)/day on days 1-14) with either cisplatin (60 mg/m(2) on day 1) or oxaliplatin (130 mg/m2 on day 1) every 3 weeks. The primary end point was overall response rate. Results: Among the 21 HCC patients, 12 and 9 patients received S-1-based chemotherapy as a first-line and salvage treatment, respectively. Partial response was seen in 5 patients and stable disease in 6. The median time-to-progression was 4.0 months (95% confidence interval [CI], 2.4-5.6) and median overall survival was 14.0 months (95% CI, 6.7-21.3). Most patients were tolerable to chemotherapy and no grade 4 toxicity was observed. Tumors with lower DPD expression were more responsive to the therapy (response rate 60.0% in lower vs. 0.0% in higher DPD, p=0.045). Conclusion: S-1 and platinum combination chemotherapy shows favorable efficacy and tolerability in advanced HCC. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | INT INST ANTICANCER RESEARCH | ko_KR |
dc.subject | Chemotherapy | ko_KR |
dc.subject | platinum | ko_KR |
dc.subject | hepatocellular carcinoma | ko_KR |
dc.subject | S-1 | ko_KR |
dc.title | Combination Chemotherapy with S-1 and Platinum in Advanced Hepatocellular Carcinoma | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김수정 | - |
dc.contributor.AlternativeAuthor | 한새원 | - |
dc.contributor.AlternativeAuthor | 오도윤 | - |
dc.contributor.AlternativeAuthor | 이남준 | - |
dc.contributor.AlternativeAuthor | 김윤준 | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.contributor.AlternativeAuthor | 윤정환 | - |
dc.contributor.AlternativeAuthor | 강경훈 | - |
dc.contributor.AlternativeAuthor | 서경석 | - |
dc.contributor.AlternativeAuthor | 방영주 | - |
dc.contributor.AlternativeAuthor | 장자준 | - |
dc.contributor.AlternativeAuthor | 김태유 | - |
dc.citation.journaltitle | ANTICANCER RESEARCH | - |
dc.description.citedreference | Lee JO, 2009, ANN ONCOL, V20, P1402, DOI 10.1093/annonc/mdp010 | - |
dc.description.citedreference | Lee JO, 2009, J GASTROEN HEPATOL, V24, P800, DOI 10.1111/j.1440-1746.2008.05672.x | - |
dc.description.citedreference | Kim JS, 2009, BRIT J CANCER, V100, P732, DOI 10.1038/sj.bjc.6604936 | - |
dc.description.citedreference | Shim JH, 2009, CANCER CHEMOTH PHARM, V63, P459, DOI 10.1007/s00280-008-0759-x | - |
dc.description.citedreference | Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026 | - |
dc.description.citedreference | Cheng AL, 2009, LANCET ONCOL, V10, P25 | - |
dc.description.citedreference | Shirasaka T, 2009, JPN J CLIN ONCOL, V39, P2, DOI 10.1093/jjco/hyn127 | - |
dc.description.citedreference | Llovet JM, 2008, NEW ENGL J MED, V359, P378 | - |
dc.description.citedreference | Nakamura M, 2008, CANCER, V112, P1765, DOI 10.1002/cncr.23356 | - |
dc.description.citedreference | UESHIMA K, 2008, ONCOLOGY S1, V75, P106 | - |
dc.description.citedreference | Boige V, 2007, BRIT J CANCER, V97, P862, DOI 10.1038/sj.bjc.6603956 | - |
dc.description.citedreference | Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep20933 | - |
dc.description.citedreference | Yeo W, 2005, J NATL CANCER I, V97, P1532, DOI 10.1093/jnci/dji315 | - |
dc.description.citedreference | Parkin DM, 2005, CA-CANCER J CLIN, V55, P74 | - |
dc.description.citedreference | Schoffski P, 2004, ANTI-CANCER DRUG, V15, P85, DOI 10.1097/01.cad.0000114631.91268.39 | - |
dc.description.citedreference | Tanioka H, 2003, ANTICANCER RES, V23, P1891 | - |
dc.description.citedreference | Milano G, 2002, CHRONOBIOL INT, V19, P177 | - |
dc.description.citedreference | Ikeguchi M, 2001, ONCOL REP, V8, P621 | - |
dc.description.citedreference | Jiang WQ, 1997, CLIN CANCER RES, V3, P395 | - |
dc.description.citedreference | SAKAMOTO S, 1993, ANTICANCER RES, V13, P631 | - |
dc.description.citedreference | YOKOYAMA I, 1991, CANCER, V68, P2095 | - |
dc.description.citedreference | NAGUIB FNM, 1985, CANCER RES, V45, P5405 | - |
dc.description.tc | 0 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.